title: Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
authors.forename: Eberhard
authors.initials: E
authors.lastname: Ritz
authors.forename: René R
authors.initials: RR
authors.lastname: Wenzel
mesh_terms: D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology; D000077868:Atrasentan; D003928:Diabetic Nephropathies / Q000150:complications*; D016232:Endothelins / Q000037:antagonists & inhibitors*; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D016232:Endothelins; D011725:Pyridines; D011743:Pyrimidines; D011759:Pyrrolidines; C484919:Avosentan; D000077868:Atrasentan